Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

184 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-20

Study Completion Date

2018-04-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is:

* to assess the efficacy of Ergoferon in treatment of influenza;
* to assess the safety of Ergoferon in treatment of influenza;
* to compare the efficacy of Ergoferon and Oseltamivir for treatment of influenza.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza

NCT01804946

Influenza

COMPLETED PHASE4

Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza

NCT05093998

Influenza

UNKNOWN PHASE3

Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children

NCT01843842

Acute Upper Respiratory Tract Infections

COMPLETED PHASE3

Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults

NCT04250311

Influenza

SUSPENDED PHASE3

Clinical Trial of Safety and Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adults

NCT01765920

Acute Upper Respiratory Tract Infections

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall duration of a patient participation in the trial is 6 days (screening/randomization/therapy onset - day 1; study therapy period - day 1-5; follow-up period - day 6).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ergoferon

The treatment period is 5 days. Oral Dose per administration: 1 tablet. The tablet should be kept in the mouth until completely dissolution, the drug is taken without regard to food intake.

Group Type EXPERIMENTAL

Ergoferon

Intervention Type DRUG

Safety and Efficacy

Oseltamivir (Tamiflu)

The treatment period is 5 days.

1 capsule (75 mg) twice a day during the meal or regardless of meal.

Group Type ACTIVE_COMPARATOR

Oseltamivir

Intervention Type DRUG

Safety and Efficacy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ergoferon

Safety and Efficacy

Intervention Type DRUG

Oseltamivir

Safety and Efficacy

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tamiflu

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients aged 18 to 70 years.
2. Patients who were admitted to hospital within 48 hours from the onset of influenza signs.
3. Patients with body temperature ≥37,8°C when visiting a doctor + severity of influenza symptoms ≥4 scores (presence of at least 1 non-specific flu symptom ≥2 scores and 1 nasal/ throat/ chest symptom ≥ 2 scores or greater number of symptoms with the severity ≥1 score).
4. Diagnosed influenza confirmed by rapid diagnostic test (OSOM Influenza A\&B Test).
5. The possibility to start therapy within 48 hours after the onset of the first symptoms of influenza.
6. Usage of contraceptive methods by both gender patients of reproductive age during the trial and within 30 days after ending the participation in the trial.
7. Availability of signed patient information sheet (Informed Consent form) for participation in the clinical trial.

Exclusion Criteria

1. Suspected pneumonia, bacterial infection or the presence of a severe disease requiring usage of antibacterial drugs (including sulphanilamides) starting from Day 1 of the disease.
2. Severe influenza with indications for hospitalization.
3. Suspected early manifestations of diseases that have symptoms similar to influenza symptoms (other acute respiratory and infectious diseases, influenza-like syndrome at the onset of systemic connective tissue disorders, hematologic neoplasms and other pathology).
4. Patients requiring concurrent antiviral products forbidden by the study.
5. Medical history of primary and secondary immunodeficiencies. а) lymphoid immunodeficiencies (Т-cell and/or В-cell, immunodeficiencies with predominant antibody deficit); b) phagocytic deficits; c) complement factor deficit; d) combined immunodeficiencies including AIDS secondary to HIV infection; toxic, autoimmune, infectious, radiation panleukopenic syndrome; total lymphocytopenic syndrome; polyclonal lymphocyte activation syndrome; postsplenectomic syndrome; congenital asplenia; abnormal immune complex syndrome associated with infectious, autoimmune and allergic diseases.
6. Medical history of sarcoidosis
7. An oncological disease/suspected oncological disease.
8. Exacerbated or decompensated chronic diseases affecting a patient's ability to participate in the clinical trial.
9. Medical history of polyvalent allergy.
10. Allergy/intolerance to any of the components of the product used for influenza therapy.
11. Impaired glucose tolerance, type 1 and type 2 diabetes mellitus.
12. Malabsorption syndrome, including congenital or acquired lactose deficiency or another disaccharide deficiency.
13. Pregnancy, breast-feeding.
14. Consumption of narcotics, alcohol \> 2 alcohol units per day, mental diseases.
15. Use of any medicine listed in the section "Prohibited concomitant treatment" within 30 days preceding the inclusion in this study.
16. Patients who, from the investigator's point of view, will fail to comply with the observation requirements of the trial or with the regimen of the study drugs.
17. Participation in other clinical studies within 1 month prior to enrollment in the current trial.
18. Patients related to the research staff of the clinical trial site who are directly involved in the trial or are the immediate family member of the researcher. The immediate family members include husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted.
19. Patients employed with OOO "NPF "MATERIA MEDICA HOLDING" (i.e., the company's employee, part-time employee under contract, or appointed official in charge of the trial, or their immediate family).

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No